期刊
JOURNAL OF CLINICAL LIPIDOLOGY
卷 7, 期 6, 页码 561-565出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2013.10.001
关键词
Cholesterol; Atherosclerosis; Lipoproteins; Statins; Lifestyle therapies; Cardiovascular risk
An international panel of the International Atherosclerosis Society has developed a new set of recommendations for management of dyslipidemia. The panel identifies non-high density lipoprotein cholesterol (non-HDL-C) as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for higher risk subjects. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins. Published by Elsevier Inc. on behalf of National Lipid Association.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据